DelveInsight’s “Alopecia Areata Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Alopecia Areata pipeline landscapes. It comprises Alopecia Areata pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alopecia Areata therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alopecia Areata pipeline products.
Some of the key takeaways of the Alopecia Areata Pipeline Report
Get an overview of pipeline landscape @ Alopecia Areata Clinical Trial Analysis
Alopecia Areata is an autoimmune skin disorder in which the hair follicles get damaged by a faulty immune system. This faultiness causes the immune system to attack its own body, disrupting hair follicles and new hair formation. The disorder can be equally witnessed in males and females, although the occurrence is mainly seen in people below 30 years. Alopecia Areata treatments include Injections, Oral, Topical Treatments and Light therapy.
Alopecia Areata Pipeline Therapeutics
Concert Pharmaceuticals is developing CTP-543 to treat mild to severe forms of Alopecia Areata. The drug acts as an oral inhibitor of Janus Kinases JAK1 AND JAK2. The research studies performed have evidently shown that inhibition of the JAKs enzymes can prove to be beneficial in the treatment of autoimmune disorders. The drug molecule CTP-543 is a deuterium modified version of the JAK1/2 inhibitor Ruxolitinib.
Research and Development Phase III NCT04518995: In November 2020, Concert Pharmaceuticals planned to initiate a multi-centre, double-blind, randomised, placebo-controlled, Phase III study of CTP-543 for patients suffering from moderate to severe Alopecia Areata. The study is estimated to be completed by March 2022, with an estimated enrollment of 700 participants.
For further information, refer to the detailed report @ Alopecia Areata Emerging Drugs
Scope of Alopecia Areata Pipeline Drug Insight
Key Questions regarding Current Alopecia Areata Treatment Landscape and Emerging Therapies Answered in the
Pipeline Report
Table of Contents
1. Alopecia Areata Report Introduction
2. Alopecia Areata Executive Summary
3. Alopecia Areata Overview
4. Alopecia Areata Analytical Perspective In-depth Commercial Assessment
5. Alopecia Areata Pipeline Therapeutics
6. Alopecia Areata Late-Stage Products (Phase III)
6.1. CTP-543: Concert Pharmaceutical
7. Alopecia Areata Mid-Stage Products (Phase II)
7.1. SHR0302: Reistone Biopharma Company
8. Alopecia Areata Early-Stage Products (Phase I)
8.1. BNZ-1: Bioniz Therapeutics
9. Alopecia Areata Preclinical Stage Products
9.1. ARQ 255: Arcutis Biotherapeutics
10. Alopecia Areata Therapeutic Assessment
11. Alopecia Areata Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Alopecia Areata Analysis
13. Alopecia Areata Key Companies
14. Alopecia Areata Key Products
15. Alopecia Areata Unmet Needs
16 . Alopecia Areata Market Drivers and Barriers
17. Alopecia Areata Future Perspectives and Conclusion
18. Alopecia Areata Analyst Views
19. Appendix
20. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr